PB0511 - Impact of Emicizumab prophylaxis on Healthcare Utilization among Hemophilia A patients

Monday, June 24, 2024

13:45 – 14:45 ICT

Room: Exhibition Hall

Presenting Author(s)

Assaf A. Barg, MD

Head of pediatric thrombosis clinic
Sheba Medical Center
Ramat Gan, HaMerkaz, Israel

Co-Author(s)

DG

Dan Geller

Physician-Researcher
Sheba Medical Center
Tel Hashomer, Tel Aviv, Israel
SL

Shadan Lalezari

Physician-Researcher
National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan 52621, Israel
Tel Hashomer, HaMerkaz, Israel
AL

Aharon Lubetsky

Physician-Researcher
National Hemophilia Center and Thrombosis & Hemostasis Institute, Sheba Medical Center, Ramat Gan 52621, Israel
Ramat Gan, HaMerkaz, Israel
OE

Orly Efros

Physician-Researcher
Sheba Medical Center
Tel Hashomer, HaMerkaz, Israel
SL

Sarina Levy-Mendelovich

Physician-Researcher
Sheba Medical Center
Ramat Gan, HaMerkaz, Israel
IB

Ivan Budnik

Senior researcher
Department of Internal Medicine, Division of Hematology/Oncology, University of Iowa, Iowa City, IA, USA
Iowa City, Illinois, United States
OC

Omri Cohen

Senior hematologist
National Hemophilia Center, Sheba Medical Center
Ramat Gan, HaMerkaz, Israel
TB

Tami Brutman-Barazani

Researcher
Sheba Medical Center
Tel Hashomer, HaMerkaz, Israel
GK

Gili Kenet

CONSULTANT PAEDIATRIC HAEMATOLOGIST
National Hemophilia Center Sheba Medical center, Tel Hashomer & Amalia Biron Research Institute of Thrombosis & Hemostasis, Tel Aviv University, Israel,
Tel Aviv, Tel Aviv, Israel

Background: Hemophilia A (HA) therapy poses a significant healthcare burden.The HAVEN 1-4 international multicenter clinical trials, have demonstrated the efficacy and safety of emicizumab. In recent years, emicizumab has been approved for prophylaxis. The current study explores the impact of transitioning to emicizumab on healthcare utilization, focusing on emergency department (ED) visits and hospitalizations in pediatric and adult HA patients.

Aims: The examine the impact of emicizumab prophylaxis on health care system utilization by comparing the number and reasons for f ED visits and hospitalizations of HA patients before and after initiation of emicizumab therapy.

Methods: Data of HA patients transitioned to emicizumab at the Israeli National Hemophilia Center was retrospectively analyzed. Demographic information, inhibitor status, treatment duration, number and reasons of ED visits and hospitalizations - were assessed.

Results: Overall, transitioning to emicizumab significantly reduced ED visits and hospitalizations. While children experienced a significant reduction in both ED visits and hospitalizations, adults showed no statistically significant change. Post-emicizumab initiation, main reasons for ED visits among children shifted from prophylactic treatment and central line associated complications to injury-related incidents.

Conclusion(s): This real-world analysis demonstrates a substantial decrease in healthcare utilization, specifically ED visits and hospitalizations, following emicizumab prophylaxis in HA patients. However, this improvement was age dependent as it was observed only among children. Further prospective studies evaluating this aspect may shed light on these findings.